Showing 2761-2770 of 4110 results for "".
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Healthy-appearing Lupus Skin Predisposed to Flares, Rasheshttps://practicaldermatology.com/news/healthy-appearing-lupus-skin-predisposed-to-flares-rashes/2461181/Normal-appearing skin of lupus patients contains the same inflammatory signals that are detected when the skin develops a rash – sometimes at even higher levels, according to a study in Science Translational Medicine. “This really starts to piece the puzzle together
- Ready for Prime Time? Ampel’s Blood Tests May Predict Drug Options for Inflammatory Skin Diseasehttps://practicaldermatology.com/news/ready-for-prime-time-ampels-blood-tests-may-predict-drug-options-for-inflammatory-skin-disease/2461179/Ampel BioSolutions machine learning approach can characterize disease activity from gene expression data obtained from patient skin biopsy and may revolutionize the way doctors treat inflammatory skin diseases, according to research published in Science Advances. The lab test
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Virtual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® Coming Soonhttps://practicaldermatology.com/news/virtual-skin-cancer-symposium-symposium-for-inflammatory-skin-disease-coming-soon/2461166/The 2nd Annual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® (SCS + SISD) will be held virtually June 10-12, 2022. Fifteen well-known speakers will deliver 15 hours of CME credit on topics such as BCC, SCC, melanoma, actinic keratosis, dermosc
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Dr. Seemal R. Desai Elected to AAD Leadershiphttps://practicaldermatology.com/news/dr-seemal-r-desai-elected-to-aad-leadership/2461161/Seemal R. Desai, MD, FAAD, has been elected to serve as president of the American Academy of Dermatology (AAD) for one year beginning in March 2024. He will be installed as president-elect in March 2023. As president, Dr. Desai will lead the wor
- New Survey Reveals Negative Impact of Psoriasis on Mental Healthhttps://practicaldermatology.com/news/new-survey-reveals-negative-impact-of-psoriasis-on-mental-health/2461159/Arcutis Biotherapeutics, Inc. recently shared findings from the Skin Insights: Uncovering Psoriasis Survey, a national survey of 507 adults 18+ diagnosed with plaque psoriasis who are on topical treatments. The online survey was conducted by The Harris Poll and was designed to reveal insight
- ICYMI: Dispatches from The Skin of Color Society’s 18th Annual Scientific Symposiumhttps://practicaldermatology.com/news/icymi-dispatches-from-the-skin-of-color-societys-18th-annual-scientific-symposium/2461157/The Skin of Color Society’s 18th Annual Scientific Symposium wowed the crowd during the American Academ